Tinnitus - Pipeline Review, H1 2018

  • ID: 4482756
  • Report
  • 61 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Pragma Therapeutics SAS
  • Sound Pharmaceuticals Inc
  • MORE
Tinnitus - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus - Pipeline Review, H1 2018, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Tinnitus - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 3, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Pragma Therapeutics SAS
  • Sound Pharmaceuticals Inc
  • MORE
Introduction

Report Coverage

Tinnitus - Overview

Tinnitus - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tinnitus - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tinnitus - Companies Involved in Therapeutics Development

AudioCure Pharma GmbH

Auris Medical Holding AG

Knopp Biosciences LLC

Otonomy Inc

Pragma Therapeutics SAS

SciFluor Life Sciences LLC

Sound Pharmaceuticals Inc

Tinnitus - Drug Profiles

AC-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ebselen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

esketamine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gacyclidine SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RL-81 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SF-0034 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Activate KCNQ for Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Kv7.2 for Central Nervous System Disorders and Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Neurotrophic Factor for Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Acute Sensorineural Hearing Loss, Presbycusis, and Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TNF-Alpha for Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetrandrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tinnitus - Dormant Projects

Tinnitus - Discontinued Products

Tinnitus - Product Development Milestones

Featured News & Press Releases

Mar 13, 2018: Auris Medical Provides Business Update

Feb 26, 2018: Auris Medical to Host Key Opinion Leader Call Focused on Keyzilen Tinnitus Program on March 5, 2018

Feb 06, 2018: Otonomy Announces Multiple Presentations for Tinnitus Program at Upcoming Association for Research in Otolaryngology Meeting

Sep 22, 2017: Auris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen in Acute and Post-Acute Tinnitus

May 09, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT1 Open-Label Extension Study

Apr 24, 2017: Auris Medical Reports Key Results from Keyzilen AMPACT 2 Open-Label Extension Study

Mar 20, 2017: Sound Pharmaceuticals announces $1.6 Million Award from Cystic Fibrosis Foundation Therapeutics to prevent and treat the hearing loss and tinnitus associated with antibiotic use

Jan 26, 2017: Auris Medical Resumes Enrollment in TACTT3 Phase 3 Trial of Keyzilen in Acute and Post-Acute Tinnitus

Dec 06, 2016: Auris Medical on Track to Resume Enrollment of Keyzilen Tinnitus Program Following Regulatory Feedback

Oct 11, 2016: Auris Medical Provides Update on Development of Keyzilen for the Treatment of Acute Inner Ear Tinnitus

Oct 10, 2016: Auris Medical to Announce Keyzilen Program Update

Sep 01, 2016: PRAGMA Therapeutics and UK Ministry of Defences Center for Defence Enterprise collaborate to support preclinical research on innovative treatment for tinnitus

Aug 18, 2016: Auris Medical Reports Top-Line Results from TACTT2 Trial with Keyzilen in Acute Inner Ear Tinnitus

Jul 19, 2016: Auris Medical Secures Loan Facility of Up To $20 Million

Jul 18, 2016: FDA Grants Auris Medical Fast Track Designation for Keyzilen in Acute Peripheral Tinnitus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Tinnitus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Tinnitus - Pipeline by AudioCure Pharma GmbH, H1 2018

Tinnitus - Pipeline by Auris Medical Holding AG, H1 2018

Tinnitus - Pipeline by Knopp Biosciences LLC, H1 2018

Tinnitus - Pipeline by Otonomy Inc, H1 2018

Tinnitus - Pipeline by Pragma Therapeutics SAS, H1 2018

Tinnitus - Pipeline by SciFluor Life Sciences LLC, H1 2018

Tinnitus - Pipeline by Sound Pharmaceuticals Inc, H1 2018

Tinnitus - Dormant Projects, H1 2018

Tinnitus - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Tinnitus, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AudioCure Pharma GmbH
  • Auris Medical Holding AG
  • Knopp Biosciences LLC
  • Otonomy Inc
  • Pragma Therapeutics SAS
  • SciFluor Life Sciences LLC
  • Sound Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll